Hospital-acquired infections are type of infections acquired during hospitalization and are commonly known as nosocomial infection. These infections can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can be acquired from an infected patient, outside environment, or from a staff of that facility. The hospital-acquired infection diagnostics market is primarily driven by the growth in awareness among healthcare workers and proposed government initiatives by many governmental organizations. Further, in developing economies such as China, India, and Brazil, the cleanliness and hygiene is minimum. Hence, it results in more hospital-acquired infections, which further increases the demand for hospital-acquired infection diagnostics. However, the decline in hospital-acquired infections in the developed countries such as the U.S., Germany, and the UK impedes the market growth. The hospital-acquired infection diagnostics market was valued at $2,571 million in 2016, and is expected to reach at $4,311 million by 2023, registering a CAGR of 7.5% from 2017 to 2023.
The hospital-acquired infection diagnostics market is segmented based on product, test type, application, infection type, end user and region. Based on product this market is segmented into instrument and reagents and consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. Based on application, the market is divided into disease testing and drug resistance testing. Further, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Based on end user this market is segmented into hospital, clinics, ambulatory surgery centres (ASC) and others. By region, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA.
Request for a FREE sample of this market research report@ https://www.reportocean.com/industry-verticals/sample-request?report_id=27122
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global hospital-acquired infections market, with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps understand the type of products and technologies used globally.
Key market players and their strategies are provided to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
Instrument and Reagents
By Test Type
Disease Testing and
By Infection Type
Hospital Acquired Pneumonia
Surgical Site Infections
Urinary Tract Infections (UTI)
Ambulatory Surgery Centers (ASC)
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
Send a request to Report Ocean to understand the structure of the complete report @ https://www.reportocean.com/industry-verticals/sample-request?report_id=27122
KEY PLAYERS PROFILED
Bayer Schering Pharma LLC
Becton Dickinson & Company
The other players in the value chain include (profiles not included in the report)
Johnson & Johnson
Merck & Co.